Triatomic Q3 2025 Private
The Q3 2025 update letter from Triatomic Capital, dated November 3 2025, informs its limited‑partner investors about the firm’s view of the accelerating AI‑driven macro environment, recent portfolio activity, and fund‑raising plans. The letter outlines a broad AI adoption wave that is reshaping labor markets – distinguishing AI‑complementary skills (high demand, premium pricing) from AI‑substituted skills (declining demand) – and quantifies the shift of total addressable market from traditional IT and advertising spend to a $50 T+ global wage‑budget. It then describes a parallel “biotech renaissance” enabled by massive data growth and AI‑native business models, highlighting Manifold Bio’s $55 M upfront partnership with Roche and its multiplexed in‑vivo drug‑screening capability. Portfolio composition is detailed (17 companies, 27 % engineered biology, 36 % next‑gen compute, etc.), along with diligence metrics (161 opportunities reviewed, 46 meetings, 9 advanced diligences). Recent investment activity includes five closed deals (three follow‑ons, two opportunistic) and several upcoming core investments, with specific company updates for Manifold Bio, Chemify, Lyten, d‑Matrix, Elegen, Teleo, MatX, iPronics, Coworker.ai, and Chalk. The firm announces the launch of Triatomic Capital Private II, notes no team changes, and provides contact information for LP outreach. Standard legal disclosures and forward‑looking statements conclude the letter.
Topics
AI‑Driven Labor Market Shift: Complementary vs Substituted Skills
Analysis of how AI adoption is bifurcating the labor market, raising demand and compensation for AI‑complementary skillsets while suppressing demand for AI‑substituted tasks.
Macro Re‑Sizing of AI Total Addressable Market to Global Wage Expenditure
Quantitative argument that AI’s impact expands the TAM from $3 T IT + $1 T ad spend to over $50 T of global wage budgets, shifting funding sources from IT/advertising to labor.
AI‑Native Biotech Renaissance and Manifold Bio’s Roche Partnership
Discussion of data‑first drug development, multiplexed in‑vivo screening, and the landmark $55 M upfront + $2 B milestone deal between Manifold Bio and Roche.
Portfolio Composition and Sector Allocation Snapshot
Current breakdown of Triatomic Capital Private I LP’s 17 companies across engineered biology, next‑gen compute, automated economy, engineered materials, and new energy, with core vs non‑core distinctions.
Recent Investment Activity and Pipeline Diligence Metrics
Summary of five closed investments (three follow‑ons, two opportunistic), upcoming core closings, and pipeline statistics (161 opportunities reviewed, 46 meetings, 9 advanced diligences).
Fund II Launch and LP Engagement Strategy
Announcement of Triatomic Capital Private II, initial institutional commitments, and outreach plan to existing LPs via Anh Wilson.
Company‑Level Updates and KPI Highlights
Specific recent developments for portfolio companies (Manifold Bio, Chemify, Lyten, d‑Matrix, Elegen, Teleo, MatX, iPronics, Coworker.ai, Chalk) including funding rounds, product milestones, and strategic hires.